2C Tech-002: Intravitreal Quantum Dots for Advanced RP
Research type
Research Study
Full title
Intravitreal Quantum Dots for Advanced Retinitis Pigmentosa (Quantum): A Pilot, Randomized, Double-masked and Sham-Controlled clinical device trial
IRAS ID
291045
Contact name
Jim Taylor
Contact email
Sponsor organisation
2C Tech Corporation Inc.
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 0 months, 2 days
Research summary
The Sponsor 2c Tech is proposing a pilot study which is randomized with observer and participant masked for their novel investigational class III medical device (2C-QD) that uses photoactive semiconducting nanotechnology particles—quantum dots (QDs)—which convert light to electrical energy to deliver electrical stimulation directly to neural retina at the cellular level. Intravitreally injected QDs have the potential to treat neurodegenerative conditions of the retina such as retinitis pigmentosa (RP), with the aim of preserving or restoring vision. It is proposed that up to 20 patients across 2 sites in the UK will be enrolled in 2021 to better understand the effectiveness of the technology in patients diagnosed with retinitis pigmentosa (RP).
REC name
London - Dulwich Research Ethics Committee
REC reference
20/LO/1231
Date of REC Opinion
6 Jan 2021
REC opinion
Further Information Favourable Opinion